Shiga Toxin Subtypes Display Dramatic Differences in Potency

ABSTRACT Purified Shiga toxin (Stx) alone is capable of producing systemic complications, including hemolytic-uremic syndrome (HUS), in animal models of disease. Stx includes two major antigenic forms (Stx1 and Stx2), with minor variants of Stx2 (Stx2a to -h). Stx2a is more potent than Stx1. Epidemiologic studies suggest that Stx2 subtypes also differ in potency, but these differences have not been well documented for purified toxin. The relative potencies of five purified Stx2 subtypes, Stx2a, Stx2b, Stx2c, Stx2d, and activated (elastase-cleaved) Stx2d, were studied in vitro by examining protein synthesis inhibition using Vero monkey kidney cells and inhibition of metabolic activity (reduction of resazurin to fluorescent resorufin) using primary human renal proximal tubule epithelial cells (RPTECs). In both RPTECs and Vero cells, Stx2a, Stx2d, and elastase-cleaved Stx2d were at least 25 times more potent than Stx2b and Stx2c. In vivo potency in mice was also assessed. Stx2b and Stx2c had potencies similar to that of Stx1, while Stx2a, Stx2d, and elastase-cleaved Stx2d were 40 to 400 times more potent than Stx1.

[1]  D. Friedmann,et al.  Molecular Basis of Differential B-Pentamer Stability of Shiga Toxins 1 and 2 , 2010, PloS one.

[2]  S. Iyer,et al.  Glycan encapsulated gold nanoparticles selectively inhibit shiga toxins 1 and 2. , 2010, Bioconjugate chemistry.

[3]  R. Cherla,et al.  Role of Tumor Necrosis Factor Alpha in Disease Using a Mouse Model of Shiga Toxin-Mediated Renal Damage , 2010, Infection and Immunity.

[4]  A. Weiss,et al.  Different Classes of Antibiotics Differentially Influence Shiga Toxin Production , 2010, Antimicrobial Agents and Chemotherapy.

[5]  V. L. Tesh,et al.  Distinct Physiologic and Inflammatory Responses Elicited in Baboons after Challenge with Shiga Toxin Type 1 or 2 from Enterohemorrhagic Escherichia coli , 2010, Infection and Immunity.

[6]  S. Iyer,et al.  Comparison of binding platforms yields insights into receptor binding differences between shiga toxins 1 and 2. , 2010, Biochemistry.

[7]  V. Gannon,et al.  Verocytotoxin-producing Escherichia coli (VTEC). , 2010, Veterinary microbiology.

[8]  H. Cook,et al.  Shiga toxin‐2 results in renal tubular injury but not thrombotic microangiopathy in heterozygous factor H‐deficient mice , 2009, Clinical and experimental immunology.

[9]  S. Satchell,et al.  Shiga Toxin 2 Targets the Murine Renal Collecting Duct Epithelium , 2009, Infection and Immunity.

[10]  Shaohua Zhao,et al.  Identification and Characterization of Shiga Toxin Type 2 Variants in Escherichia coli Isolates from Animals, Food, and Humans , 2008, Applied and Environmental Microbiology.

[11]  C. Silberstein,et al.  Inhibition of water absorption in human proximal tubular epithelial cells in response to Shiga toxin-2 , 2008, Pediatric Nephrology.

[12]  T. Whittam,et al.  Pathogenesis of Renal Disease Due to Enterohemorrhagic Escherichia coli in Germ-Free Mice , 2008, Infection and Immunity.

[13]  T. Whittam,et al.  Variation in virulence among clades of Escherichia coli O157:H7 associated with disease outbreaks , 2008, Proceedings of the National Academy of Sciences.

[14]  N. Lago,et al.  Development of an experimental hemolytic uremic syndrome in rats , 2008, Pediatric Nephrology.

[15]  S. Iyer,et al.  Differentiation between structurally homologous Shiga 1 and Shiga 2 toxins by using synthetic glycoconjugates. , 2008, Angewandte Chemie.

[16]  A. Gobert,et al.  Differential expression of stx2 variants in Shiga toxin-producing Escherichia coli belonging to seropathotypes A and C. , 2008, Microbiology.

[17]  T. Haga,et al.  Relationship between pathogenicity for humans and stx genotype in Shiga toxin-producing Escherichia coli serotype O157 , 2008, European Journal of Clinical Microbiology & Infectious Diseases.

[18]  P. Sheridan,et al.  Phylogenetic analysis of Shiga toxin 1 and Shiga toxin 2 genes associated with disease outbreaks , 2007, BMC Microbiology.

[19]  M. Dierich,et al.  The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome. , 2007, Diagnostic microbiology and infectious disease.

[20]  G. Armstrong,et al.  Affinities of Shiga toxins 1 and 2 for univalent and oligovalent Pk-trisaccharide analogs measured by electrospray ionization mass spectrometry. , 2007, Glycobiology.

[21]  G. Fernández,et al.  Role of Polymorphonuclear Leukocytes in the Pathophysiology of Typical Hemolytic Uremic Syndrome , 2007, TheScientificWorldJournal.

[22]  F. Scheutz,et al.  Subtyping Method for Escherichia coli Shiga Toxin (Verocytotoxin) 2 Variants and Correlations to Clinical Manifestations , 2007, Journal of Clinical Microbiology.

[23]  A. Friedrich,et al.  Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  C. Silberstein,et al.  Cytotoxic effect of Shiga toxin-2 holotoxin and its B subunit on human renal tubular epithelial cells. , 2006, Microbes and infection.

[25]  J. Ingelfinger,et al.  Shiga toxin enhances functional tissue factor on human glomerular endothelial cells: implications for the pathophysiology of hemolytic uremic syndrome * , 2005, Journal of thrombosis and haemostasis : JTH.

[26]  J. Pohlenz,et al.  Shiga-Toxigenic Escherichia coli-Inoculated Neonatal Piglets Develop Kidney Lesions That Are Comparable to Those in Humans with Hemolytic-Uremic Syndrome , 2005, Infection and Immunity.

[27]  A. Blanch,et al.  Diversity of stx2 converting bacteriophages induced from Shiga-toxin-producing Escherichia coli strains isolated from cattle. , 2004, Microbiology.

[28]  Steen Ethelberg,et al.  Virulence Factors for Hemolytic Uremic Syndrome, Denmark , 2004, Emerging infectious diseases.

[29]  T. Yutsudo,et al.  Rapid Apoptosis Induced by Shiga Toxin in HeLa Cells , 2003, Infection and Immunity.

[30]  D. Miyamoto,et al.  Restricted Expression of Shiga Toxin Binding Sites on Mucosal Epithelium of Mouse Distal Colon , 2003, Infection and Immunity.

[31]  T. Pysher,et al.  Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome , 2003, Pediatric Nephrology.

[32]  B. Binnington,et al.  Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model. , 2002, Kidney international.

[33]  L. Teel,et al.  One of Two Copies of the Gene for the Activatable Shiga Toxin Type 2d in Escherichia coli O91:H21 Strain B2F1 Is Associated with an Inducible Bacteriophage , 2002, Infection and Immunity.

[34]  P. Sherman,et al.  Escherichia coli Shiga-Like Toxins Induce Apoptosis and Cleavage of Poly(ADP-Ribose) Polymerase via In Vitro Activation of Caspases , 2002, Infection and Immunity.

[35]  A. Friedrich,et al.  Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. , 2002, The Journal of infectious diseases.

[36]  R. Morona,et al.  Neutralization of Shiga Toxins Stx1, Stx2c, and Stx2e by Recombinant Bacteria Expressing Mimics of Globotriose and Globotetraose , 2001, Infection and Immunity.

[37]  B. Zanke,et al.  Escherichia coli Shiga toxins induce apoptosis in epithelial cells that is regulated by the Bcl-2 family. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[38]  R. Read,et al.  A mutant Shiga-like toxin IIe bound to its receptor Gb(3): structure of a group II Shiga-like toxin with altered binding specificity. , 2000, Structure.

[39]  M. Mizuno,et al.  Synthesis of an artificial glycoconjugate polymer carrying Pk-antigenic trisaccharide and its potent neutralization activity against Shiga-like toxin. , 1999, Bioorganic & medicinal chemistry.

[40]  S. McEwen,et al.  Associations between Virulence Factors of Shiga Toxin-ProducingEscherichia coli and Disease in Humans , 1999, Journal of Clinical Microbiology.

[41]  R J Read,et al.  Structure of the shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. , 1998, Biochemistry.

[42]  A. Caprioli,et al.  Apoptosis of Renal Cortical Cells in the Hemolytic-Uremic Syndrome: In Vivo and In Vitro Studies , 1998, Infection and Immunity.

[43]  C. Le Bouguénec,et al.  Enteric infections due to Escherichia coli. , 1998, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[44]  J. Wells,et al.  Escherichia coli 0157 : H 7 Diarrhea in the United States : Clinical and Epidemiologic Features , 2009 .

[45]  A. O’Brien,et al.  Activation of Shiga-like toxins by mouse and human intestinal mucus correlates with virulence of enterohemorrhagic Escherichia coli O91:H21 isolates in orally infected, streptomycin-treated mice , 1996, Infection and immunity.

[46]  Serotype O104H.  Outbreak of acute gastroenteritis attributable to Escherichia coli serotype O104:H21--Helena, Montana, 1994. , 1995, MMWR. Morbidity and mortality weekly report.

[47]  J. Samuel,et al.  Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice , 1993, Infection and immunity.

[48]  H. Lior,et al.  Diarrhoea in close contacts as a risk factor for childhood haemolytic uraemic syndrome , 1993, Epidemiology and Infection.

[49]  G. Tyrrell,et al.  Alteration of the carbohydrate binding specificity of verotoxins from Gal alpha 1-4Gal to GalNAc beta 1-3Gal alpha 1-4Gal and vice versa by site-directed mutagenesis of the binding subunit. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[50]  M. P. Jackson,et al.  Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. , 1992, Current topics in microbiology and immunology.

[51]  C. Gyles,et al.  Reproduction of Edema Disease of Swine with Purified Shiga-like Toxin-II Variant , 1991, Veterinary pathology.

[52]  R. Tauxe,et al.  The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. , 1991, Epidemiologic reviews.

[53]  L. M. Sung,et al.  Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II , 1990, Infection and immunity.

[54]  S. Ostroff,et al.  Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. , 1989, The Journal of infectious diseases.

[55]  T. Yutsudo,et al.  Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. , 1988, European journal of biochemistry.

[56]  J. Carlson,et al.  A severe outbreak of Escherichia coli O157:H7--associated hemorrhagic colitis in a nursing home. , 1987, The New England journal of medicine.

[57]  R. Holmes,et al.  Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities , 1986, Infection and immunity.

[58]  G. Keusch,et al.  Pathogenesis of shigella diarrhea: evidence for an N-linked glycoprotein shigella toxin receptor and receptor modulation by beta-galactosidase. , 1986, The Journal of infectious diseases.

[59]  R. Holmes,et al.  Shiga-like toxin-converting phages from Escherichia coli strains that cause hemorrhagic colitis or infantile diarrhea. , 1984, Science.